| Name | Title | Contact Details |
|---|
LifeLine Financial captains fast-growing businesses nationwide in service, technology, retail, and trades. We offer exceptional bookkeeping and accounting services nationwide. Call us today and grab a LifeLine (603) 782-4663
Qualitas is a full-service consulting firm dedicated to quality results for our clients. We provide expert advice and technical support for business processes and tools, especially Contract Lifecycle Management (CLM) and Enterprise Legal Management (ELM) solutions. We are passionate about helping our clients achieve long‑lasting success, and we are proud to be a woman-owned business.
Strategic growth advisor to FinTech and Wealth Management organizations
Sisu is an industry thought leader in the fields of robotics and automation. We take on complex engineering problems that often involve adopting or inventing new technologies. We are disrupting the cinema, industrial knife sharpening, welding, and other industries. With robots that are easy to program, its no wonder that we are one of the fastest-growing cinema robotics companies in the world! We provide a fast-paced and exciting work environment, built on values of hard work and family, attracting top talent from across the country. Sisu is located in beautiful Austin Texas and serves customers in the United States and around the world. Sisu is a Kuka Robotics System Partner and an alliance partner with National Instruments.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.